Zocor Articles
Atorvastatin More Effective Than Simvastatin
16 July 1997
Lipobay Selected For Large UK Study In Diabetics
24 June 1997
FDA Approves New Zocor Recommendations
9 June 1997
Merck & Co To File Zocor 80mg In USA
26 May 1997
Forex Impacts Sales At Pfizer, Merck And S-P
22 April 1997
NEW YORK STOCK COMMENT
10 April 1997
First Launch Of Bayer's Lipobay
9 April 1997
Merck's Zocor "Effective" In Diabetics With CHD
9 April 1997
Lipitor To Drive Outperformance At W-L?
14 March 1997
NEW YORK STOCK COMMENT
10 March 1997
US Rx Drug Sales For 1996 Up 10% At $85.35 Billion
24 February 1997
First Launch Of Parke-Davis' Lipitor
10 February 1997
Strong Earnings Continue At Major US Drug Firms
10 February 1997
Fournier Fights Back Over Generics Case
27 January 1997
Zocor "Will Be World's Top-Selling Drug In 2005"
13 January 1997
Astra's Losec "World's No One Drug In 1998-2000"
16 December 1996
Atorvastatin: 1st Approvals In UK And Germany
9 December 1996
Good Japanese Interim Results, Despite Price Cuts
25 November 1996
Meta-Analysis Finds Statins Cut Stroke
25 November 1996
New Statin Data Should Benefit Female Patients
25 November 1996
Statins Market In Europe Set For Growth, IMS Study Forecasts
23 September 1996
US Drug Majors See 2nd-Half Double-Digit Growth
29 July 1996
Lipovas Boosts Banyu
17 June 1996
Zocor In Canada
20 May 1996
US Firms' Strong 1st Qtr Lifts Share Prices
29 April 1996
Pipeline Contains Two Blockbusters, Says W-L
22 April 1996
11% 1st-Qtr EPS Rise From US Drug Cos
15 April 1996
CARE Reinforces Statin Role After Heart Attack
8 April 1996
World Pharma Sales Up 11.6% In 1995, Says PMSI
18 March 1996
Sweden's Pharma Market Expanded 12.7% In 1995
4 March 1996
Losec "Will Be The World's Top-Selling Drug In 2000"
26 February 1996
Merck & Co Moves Into French Generics Battle
19 February 1996
All Change For Top Drugs In Year 2000: Lehman Bros
15 January 1996
EU Iberian P-I Ruling And The Dutch Market
8 January 1996
Pravastatin Prevents First Heart Attack; WOS Study
27 November 1995
US FTC "Must Monitor Company/PBM Deals"
20 November 1995
Greek Drug Prices "Much Higher Than EU Average"
13 November 1995
US Drug Cos Reveal Strong Growth In 1995 3rd Qtr
30 October 1995
Five-Year BECAIT Data Reveal Fibrate Benefit
18 September 1995
FDA Approves Zocor Label Change
10 July 1995
Tokyo stock comment
19 June 1995
The ABPI's A-Z Of British Medicines Research
29 May 1995
Disease ManagementThe Way Forward
15 May 1995
Tokyo STOCK COMMENT
24 April 1995
Losec Europe's Top-Selling Product
10 April 1995
Atorvastatin Treatment IND Approved
13 March 1995
January Rx Trends In The USA
13 March 1995
Simvastatin Improves Survival; 4S Study
28 November 1994
South African Pharma Market $4 Billion In 2002
21 November 1994
Hyperlipidemia Market Poised For Expansion
14 November 1994
Hoechst Streamlines R&D: Update On Early Pipeline
10 October 1994
Lowering Lipids In Atheroma; MAAS
12 September 1994
Benefits From PBM/MPC Acquisitions Assessed
15 August 1994
Strong Gains By US Firms In 2nd Quarter
1 August 1994
Zocor Agreement
18 July 1994
MERCK/SANDOZ VIE FOR MARKET SHARE
27 June 1994
MERCK & CO POSTS 10% PR0FIT RISE
25 April 1994
PRICE WAR LOOMING FOR HYPOLIPEMICS
28 March 1994
JAPANESE DRUG PRICE CUTS AVERAGE 7.4%
21 March 1994
JAPAN PHARMA MARKET IS LARGE, POOR PERFORMER
14 March 1994
JAPANESE DRUG REIMBURSEMENT CUTS
14 February 1994
LIKELY IMPACT ON DRUG FIRMS OF ITALIAN REFORMS
17 January 1994
FDA YEAR-END APPROVALS FOR 1993
10 January 1994
DRUGMAKERS IN ITALY PANIC ON NEW SALES FEARS
10 January 1994
JAPAN TO LOWER IFN, HYPOLIPEMIC PRICES
20 December 1993
US 3rd QTR RESULTS MIXED AS DRUG IND CUTS BACK
25 October 1993
OXFORD SIMVASTATIN MORTALITY STUDY
20 September 1993
NEW TRIAL SET FOR HYPOLIPEMICS
6 September 1993
TANABE AND SANDOZ IN DRUG ALLIANCE
2 August 1993
US PRESCRIBING TRENDS IN MARCH
28 June 1993
SB AND J&J TO COPROMOTE IN USA
24 May 1993
PRICE FLEXIBILITY AND THE DRUG INDUSTRY
12 April 1993
JOB CUTS AND EARNINGS WARNING FROM MERCK
5 April 1993
MERCK CUTS PRICE OF TWO DRUGS
29 March 1993
MERCK CANADA MOVES TO WARD OFF COMPETITION
1 March 1993
RECORD RESULTS FROM US PHARMA MAJORS
1 February 1993
ABPI CODE OF PRACTICE LATEST REPORT
21 December 1992
MERCK & CO EARNINGS ESTIMATES LOWERED
14 December 1992
BUSINESS IMPROVING FOR JAPANESE COMPANIES
14 December 1992
Merck's Zocor: clinical trial
22 June 1992
FALL IN PROFITS AT BANYU
22 June 1992
MERCK CLAIMS EFFICACY ADVANTAGE FOR STATINS
1 June 1992
MARS STUDY REVEALS NEW REGRESSION DATA
25 May 1992
GOOD SALES GROWTH FOR MAJOR US COS IN 1st QTR
27 April 1992
POST-ELECTION OUTLOOK FOR UK HEALTH SECTOR
20 April 1992
HYPOLIPIDEMICS INFO
23 March 1992
MEVACOR WORKS IN FDB, SAYS STUDY
16 March 1992
MS&D GREECE SALES RISE 19%
3 February 1992
BANYU PINS HOPESON LIPOVAS
20 January 1992
DECEMBER US APPROS REVIEWED
20 January 1992
US FDA BEATS 1990 DRUG APPROVALS IN 1991
13 January 1992
SB JOINS MERCK TO MARKET ZOCOR
6 January 1992
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
